The BAFF-APRIL Pathway: A Core Regulatory Axis of the TNF Superfamily

The B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), along with their receptors—BAFFR, TACI, and BCMA—constitute a core functional subset of the Tumor Necrosis Factor (TNF) and its receptor superfamilies.
This functionally integrated network is established through specific ligand-receptor binding, and it is crucial for regulating the survival, proliferation, and differentiation of B lymphocytes. Consequently, its dysregulation is closely linked to autoimmune diseases and B-cell malignancies, such as multiple myeloma.
BAFF and APRIL receptor interactions.

BAFF and APRIL receptor interactions.
Resource:DOI: 10.1080/08830185.2016.1276903

Pathological Significance in Disease

The BAFF-APRIL family acts as the core signaling axis for B-cell survival and activation. Dysregulation, such as excessive signal activation, directly compromises immune tolerance, thereby triggering or exacerbating a range of severe diseases:
Autoimmune Diseases B-Cell Malignancies Immunodeficiency Diseases
Overexpression of BAFF/APRIL drives autoreactive B-cell activation and autoantibody production, exacerbating conditions like Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).
BCMA is highly expressed on multiple myeloma cells, making it a critical target for next-generation therapies like CAR-T and ADCs. Additionally, APRIL overexpression is linked to B-cell lymphoma progression.
BAFFR gene mutations are associated with Common Variable Immunodeficiency (CVID)

Enabling Research and Drug Development

To meet the growing demand for drug development and mechanistic research targeting this vital pathway, we have developed a comprehensive, full-chain product portfolio. This portfolio supports core research scenarios—from disease biomarker discovery to targeted drug development and BAFF pathway mechanism analysis—helping researchers overcome challenges throughout the entire workflow.

Product Features

High Purity verified by SEC-MALS/HPLC.

Native Conformation confirmed by SEC-MALS.

High Bioactivity validated by ELISA/SPR/FACS.

Strict QC Inspection Ensures High Batch-to-Batch Consistency

Product List

BAFF
BAFFR
APRIL
TACI
BCMA
Cat. No.MoleculeNatureProduct DescriptionOrder Now
Protein
Order
Protein
Order
Protein
Order
Protein
Order
Protein
Order
Protein
Order
Protein
Order
Protein
Order
Protein
Order
Protein
Order
Protein
Order
Protein
Order
Protein
Order
Protein
Order

Validated Data

Trimeric structure verified by SEC-MALS

SDS-PAGE

SDS-PAGE

Biotinylated Human BAFF Protein, His, Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

SEC-MALS

The purity of Biotinylated Human BAFF Protein, His, Avitag (Cat. No. BAF-H82Q2) is more than 90% and the molecular weight of this protein is around 60-75 kDa verified by SEC-MALS.

Request Report

High binding affinity of BAFF to BAFFR/BCMA/TACI validated by ELISA

High binding affinity of BAFF to BAFFR/BCMA/TACI validated by ELISA

Immobilized Human BCMA, Mouse IgG2a Fc Tag (Cat. No. BCA-H5253) at 1 μg/mL (100 μL/well) can bind Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) with a linear range of 0.2-6 ng/mL (QC tested).

Request Protocol
High binding affinity of BAFF to BAFFR/BCMA/TACI validated by ELISA

Immobilized Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) at 1 μg/mL (100 μL/well) can bind Biotinylated Human TACI, Fc, Avitag (Cat. No. TAI-H82F6) with a linear range of 0.002-0.05 μg/mL (Routinely tested).

Request Protocol
High binding affinity of BAFF to BAFFR/BCMA/TACI validated by ELISA

Immobilized Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) at 1 μg/mL (100 μL/well) can bind Biotinylated Mouse BAFFR, Fc, Avitag (Cat. No. BAR-M82F0) with a linear range of 0.4-25 ng/mL (Routinely tested).

Request Protocol
High binding affinity of BAFF to BAFFR/BCMA/TACI validated by ELISA

Immobilized Human BCMA, Fc Tag (Cat. No. BC7-H5254) at 2 μg/mL (100 μL/well) can bind Biotinylated Human BAFF Protein, His, Avitag (Cat. No. BAF-H82Q2) with a linear range of 0.2-4 ng/mL (QC tested).

Request Protocol

High binding affinity of BAFF to BAFF-BAFFR/TACI validated by SPR

High binding affinity of BAFF to BAFF-BAFFR/TACI validated by SPR

Immobilized Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) on CM5 Chip can bind Human TACI Protein, Fc Tag with an affinity constant of 0.658 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Request Protocol
High binding affinity of BAFF to BAFF-BAFFR/TACI validated by SPR

Immobilized Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human BAFFR Protein, Llama IgG2b Fc Tag (Cat. No. BAR-H5258) with an affinity constant of 44.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested). Protocol BAR-H5258

Request Protocol

High binding affinity of BAFF to BCMA validated by BLI

High binding affinity of BAFF to BCMA validated by BLI

Loaded Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) on Protein A Biosensor, can bind Biotinylated Human BCMA, His, Avi-tag (Cat. No. BCA-H82E4) with an affinity constant of 0.69 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Request Protocol

BAFF's activity in stimulating mouse splenocyte proliferation verified

BAFF's activity in stimulating mouse splenocyte proliferation verified

Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) stimulates proliferation of mouse spleen cells. The EC50 for this effect is 4.91-9.81 ng/mL (Routinely tested).

Request Protocol

High binding affinity of APRIL to BCMA/TACI validated by ELISA

High binding affinity of APRIL to BCMA/TACI validated by ELISA

Immobilized Human BCMA, Fc Tag (Cat. No. BC7-H5254) at 2 μg/mL (100 μL/well) can bind Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) with a linear range of 10-39 ng/mL (QC tested).

Request Protocol
High binding affinity of BAFF to BCMA validated by BLI

Immobilized Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) at 1 μg/mL (100 μL/well) can bind Human TACI Protein, Fc Tag with a linear range of 0.8-25 ng/mL (Routinely tested).

Request Protocol

High binding affinity of APRIL to BCMA/TACI validated by BLI

High binding affinity of APRIL to BCMA/TACI validated by BLI

Loaded Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human BCMA, Fc Tag (Cat. No. BC7-H5254) with an affinity constant of 1.88 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Request Protocol
High binding affinity of APRIL to BCMA/TACI validated by BLI

Loaded Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human TACI Protein, Fc Tag with an affinity constant of 75 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Request Protocol

Clinical Drug Information Table of BAFF-APRIL Pathway

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
BCMA-UCARTBCMA-UCARTClinicalBRL Medicine IncMultiple Myeloma
Details
bispecific anti-CD19/anti-BCMA CAR T-cell therapy (Shanghai Hrain Biotechnology)HRAIN-002ClinicalHrain Biotechnology Co LtdMultiple Myeloma
Details
anti-BCMA/NKG2DL/FAP TCR T-cell therapy (Guangdong VitaLife)ClinicalGuangdong Vitalife Biotechnology Co LtdMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy (Shanghai GeneChem)ClinicalShanghai Genechem Co LtdMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy engineered to express anti-IL6 scFv and IL1RA (Celledit)ClinicalCelledit LlcLymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
anti-BMCA CAR NK-cell therapy (Hangzhou Cheetah Cell Therapeutics/Zhejiang University)ClinicalZhejiang UniversityMultiple Myeloma
Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)ClinicalHuazhong University Of Science And TechnologyMultiple Myeloma
Details
APRIL CAR-T Cell therapy (Yake Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma
Details
RO-7297089RO-7297089; AFM-26; RG-6296Phase 1 ClinicalGenentech IncMultiple Myeloma
Details
AritinerceptAUR-200; AUR200Phase 1 ClinicalThunderbolt Pharma IncAutoimmune Diseases
Details
anti-TriPRIL CAR T-cell therapy(Massachusetts General Hospital)Phase 1 ClinicalMassachusetts General HospitalMultiple Myeloma
Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)Phase 1 ClinicalActavis Inc, Eugia Pharma Specialities LtdMultiple Myeloma
Details
KD-6005KD-6005; KD6005Phase 1 ClinicalShanghai Celgen Bio-Pharmaceutical Co Ltd, Shanghai Kanda Bio-Technology Co LtdArthritis, Rheumatoid
Details
JADE-001JADE-001; JADE001; PR030; PR-030; JADE101; JADE-101Phase 1 ClinicalParagon Therapeutics IncGlomerulonephritis, IGA
Details
GenSci-136GenSci136Phase 1 ClinicalChangchun GeneScience Pharmaceuticals Co LtdAutoimmune Diseases; Glomerulonephritis, IGA; Lupus Erythematosus, Systemic; Myasthenia Gravis; Sjogren's Syndrome
Details
SSS-68SSS68; SSS-68Phase 1 ClinicalShenyang Sunshine Pharmaceutical Co LtdGlomerulonephritis, IGA
Details
BCMA-CD19 cCARPhase 1 ClinicaliCell Gene Therapeutics LLCLupus Erythematosus, Systemic; Lupus Nephritis; Multiple Myeloma; Neuromyelitis Optica; Rejection of organ transplantation; Waldenstrom Macroglobulinemia
Details
CBG-002CBG-002Phase 1 ClinicalCarbiogene Therapeutics Co LtdMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy (Yake Biotechnology/Zhejiang University)Phase 1 ClinicalShanghai Yake Biotechnology Co LtdMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy (Kite)FHVH33-CD8BBZPhase 1 ClinicalTeneobio IncMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy (National Cancer Institute)Phase 1 ClinicalNational Cancer InstituteMultiple Myeloma
Details
BCMA-CS1 cCAR T-cell therapyPhase 1 ClinicaliCell Gene Therapeutics LLCMultiple Myeloma
Details
dual anti-BCMA/anti-CD38 CAR T-cell therapy (Shengyan Pharmaceutical Technology/Tongji Medical College)Phase 1 ClinicalTongji Medical CollegeMultiple Myeloma
Details
dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology)Phase 1 ClinicalWuhan Sian Biotechnology Co LtdMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityMultiple Myeloma
Details
IM-21IM21; IM-21Phase 1 ClinicalImunopharm Technology Co LtdMultiple Myeloma
Details
CLYM-116CLYM116; MIL116Phase 2 ClinicalBeijing Mabworks Biotech Co LtdGlomerulonephritis, IGA
Details
PovetaciceptALPN-303; ALPN 30xPhase 3 ClinicalAlpine Immune Sciences IncAnemia, Hemolytic, Autoimmune; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cytopenia; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Inflammation; Lupus Erythematosus, Systemic; Lupus Nephritis; Myasthenia Gravis; Nephrosis; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome
Details
ZigakibartBION-1301; FUB523; FUB-523Phase 3 ClinicalAduro Biotech IncGlomerulonephritis, IGA; Multiple Myeloma; Proteinuria
Details
BAFFR-CAR T cell therapy (PeproMene Bio)PMB-101; PMB-CT01Phase 1 ClinicalCity Of Hope National Medical Center, PeproMene Bio IncLeukemia, Biphenotypic, Acute; Lymphoma, B-Cell; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Details
JH-013JH-013Phase 1 ClinicalBiotech Pharmaceuticals Co LtdArthritis, Rheumatoid; Hematologic Neoplasms; Lupus Erythematosus, Systemic; Sjogren's Syndrome
Details
AritinerceptAUR-200; AUR200Phase 1 ClinicalThunderbolt Pharma IncAutoimmune Diseases
Details
KD-6005KD-6005; KD6005Phase 1 ClinicalShanghai Celgen Bio-Pharmaceutical Co Ltd, Shanghai Kanda Bio-Technology Co LtdArthritis, Rheumatoid
Details
CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang UniversityAutoimmune Diseases; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Details
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells therapy(Mayo Clinic)MC10029; MC-10029Phase 1 ClinicalMayo ClinicLeukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell
Details
LY-4152199LY-4152199; LY4152199Phase 1 ClinicalEli Lilly And CompanyLymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin
Details
BAFFR CAR-T cell therapy (Bio-gene Technology)Phase 1 ClinicalGuangzhou Bio-Gene Technology Co LtdPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Details
BAFF-R CAR-T cells therapy (Topcel-KH Pharmaceutical)Phase 1 ClinicalJiangsu Topcel-KH Pharmaceutical Co LtdLymphoma, B-Cell
Details
SSS-68SSS68; SSS-68Phase 1 ClinicalShenyang Sunshine Pharmaceutical Co LtdGlomerulonephritis, IGA
Details
dual anti-CD19/anti-BAFF CAR T-cell therapy (Shanghai YaKe Biotechnology/Zhejiang University)Phase 1 ClinicalShanghai Yake Biotechnology Co LtdAutoimmune Diseases; Dermatomyositis; Lupus Erythematosus, Systemic; Nephritis; Neuromyelitis Optica; Scleroderma, Systemic
Details
ESG-206ESG-206Phase 2 ClinicalShanghai Escugen Biotechnology Co LtdLupus Erythematosus, Systemic; Lymphoma, B-Cell; Neoplasms; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome
Details
Anti-BAFFR CAR T therapy(The General Hospital Of Tianjin Medical University)BAFFR CARTPhase 2 ClinicalThe General Hospital Of Tianjin Medical UniversityMyasthenia Gravis; Myositis; Neuromyelitis Optica; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Details
Fully Human BAFF-R Chimeric Antigen Receptor T-Cell (Taihe Chunyu)Phase 2 ClinicalHebei Tahoe Chunyu Biotechnology Co LtdLeukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Waldenstrom Macroglobulinemia
Details
BCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics)UTAA17ClinicalPersongen Biotherapeutics (Suzhou) Co LtdMultiple Myeloma
Details
PD-1Ab21-BCMACAR-T (CD biopharma)CD-003; CD-203ClinicalCD (Suzhou) Biopharma Co LtdMultiple Myeloma
Details
Anti-BCMA chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics)ClinicalMultiple Myeloma
Details
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics)ACT-001(Acellytron Therapeutics)ClinicalAcellytron TherapeuticsMultiple Myeloma
Details
CT-059XCT-059X; CT059XClinicalCARsgen Therapeutics Holdings LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
ECAR-01ECAR-01; ECAR01ClinicalAnhui Provincial HospitalAutoimmune Diseases
Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)ClinicalHuazhong University Of Science And TechnologyMultiple Myeloma
Details
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology)ClinicalWuhan BioRaid Biotechnology Co LtdHematologic Neoplasms
Details
CC-98633CC-98633Phase 1 ClinicalCelgene CorpMultiple Myeloma
Details
C-4-29Phase 1 ClinicalChongqing Precision Biotechnology Co LtdCarcinoma, Renal Cell; Lupus Erythematosus, Systemic; Multiple Myeloma
Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang UniversityAutoimmune Diseases; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nephritis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome
Details
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech)LCAR-BCXPhase 1 ClinicalMultiple Myeloma
Details
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital)Phase 1 ClinicalChongqing Xinqiao HospitalMultiple Myeloma
Details
JWCAR129JWCAR129; JWCAR-129Phase 1 ClinicalSuzhou Yaomingjunuo Biotechnology Co LtdMultiple Myeloma
Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityMultiple Myeloma
Details
CizutamigEMB-06; CND-106; CN106Phase 1 ClinicalShanghai Epimab Biotherapeutics, IncColitis, Ulcerative; Food Hypersensitivity; Graves Ophthalmopathy; Hypersensitivity, Immediate; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis; Pemphigus; Scleroderma, Systemic
Details
AUTO-8AUTO-8Phase 1 ClinicalAutolus Therapeutics PlcMultiple Myeloma
Details
ALLO-605ALLO-605; ALLO605Phase 1 ClinicalCellectis Sa, Overland Pharmaceuticals (Shanghai) Co LtdMultiple Myeloma
Details
MCM-998MCM-998; LXG-250Phase 1 ClinicalNovartis Pharma AgMultiple Myeloma
Details
PHE-885PHE-885Phase 1 ClinicalNovartis Pharma AgHematologic Neoplasms; Multiple Myeloma
Details
KJ-C2111CT-0590; KJ-C2111Phase 1 ClinicalCARsgen Therapeutics Holdings LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
BCMA-NKEBCMA-NKEPhase 1 ClinicalBristol-Myers Squibb CompanyMultiple Myeloma
Details
IBI-346IBI-346Phase 1 ClinicalMultiple Myeloma
Details
MEDI-2228MEDI-2228Phase 1 ClinicalMedimmune LlcMultiple Myeloma
Details
HY-027HY-027Phase 1 ClinicalJuventas Cell Therapy LtdMultiple Myeloma
Details
OriC-321OriC-321; Ori-C-321Phase 1 ClinicalOriCell Therapeutics Co Ltd, Zhejiang UniversityMultiple Myeloma
Details
ISB-2001ISB-2001; ABBV-2001Phase 1 ClinicalIchnos Sciences SaMultiple Myeloma
Details
MCARH-125MCARH-125Phase 1 ClinicalMemorial Sloan Kettering Cancer CenterMultiple Myeloma
Details
BRL-302BRL-302Phase 1 ClinicalBRL Medicine IncAutoimmune Diseases; Lupus Nephritis; Multiple Sclerosis; Myasthenia Gravis; Neuromyelitis Optica; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours
Details
LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co)Phase 1 ClinicalMultiple Myeloma
Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)Phase 1 ClinicalActavis Inc, Eugia Pharma Specialities LtdMultiple Myeloma
Details
Anti-BCMA CAR T (Nanjing Kati Medical Technology)Phase 1 ClinicalNanjing Kati Medical Technology Co LtdMultiple Myeloma
Details
BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma)SWK001; SWK-001Phase 1 ClinicalHunan Siweikang Pharmaceutical Co LtdMultiple Myeloma
Details
BCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics)CBG-002 CAR-TPhase 1 ClinicalCarbiogene Therapeutics Co LtdMultiple Myeloma
Details
Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering)Phase 1 ClinicalHualan Genetic Engineering (Henan) Co LtdMultiple Myeloma
Details
SIM-0500SIM-0500; SIM0500Phase 1 ClinicalSimcere Pharmaceutical Group LtdBone Marrow Neoplasms; Multiple Myeloma
Details
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics)BMS-986453Phase 1 ClinicalJuno Therapeutics IncMultiple Myeloma
Details
YKST-02YKST02; YKST-02Phase 1 ClinicalExcyte Biopharma LtdMultiple Myeloma
Details
The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine)FKC-288; FKC288Phase 1 ClinicalNanjing University School Of MedicineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, Membranous; Immunoglobulin G4-Related Disease; Lupus Nephritis
Details
KLN-1010KLN-1010Phase 1 ClinicalKelonia Therapeutics IncBlood Protein Disorders; Hemostatic Disorders; Immune System Diseases; Immunoproliferative Disorders; Lymphoproliferative Disorders; Multiple Myeloma; Neoplasms; Paraproteinemias; Vascular Diseases
Details
SYS-6020SYS6020; SYS-6020Phase 1 ClinicalCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdLupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis
Details
CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital)Phase 1 ClinicalWuhan Union HospitalLupus Erythematosus, Systemic
Details
BCMA CAR-NK (Hrain Biotechnology)HR012Phase 1 ClinicalHrain Biotechnology Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
RD-140RD140Phase 1 ClinicalNanjing Iaso Biotherapeutics Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
Zirconium-89 belantamab89Zr-GSK2857914Phase 1 ClinicalGlaxosmithkline PlcMultiple Myeloma; Neoplasms
Details
QLS-4131QLS-4131; QLS4131Phase 1 ClinicalQilu Pharmaceutical Co LtdLupus Erythematosus, Systemic; Multiple Myeloma
Details
Anti-CD19/BCMA CAR T-cell therapy(YaKe Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang UniversityLupus Erythematosus, Systemic; Lupus Nephritis
Details
OL-101OL-101Phase 1 ClinicalOverland Pharmaceuticals (Shanghai) Co LtdMultiple Myeloma
Details
BZE-2204BZE2204; BZE-2204Phase 1 ClinicalShanghai Cell Therapy Group Co LtdLupus Erythematosus, Systemic; Lymphoma, B-Cell; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic
Details
PRG-2311PRG-2311Phase 1 ClinicalShenzhen Pregene Biopharma Co LtdImmunoglobulin G4-Related Disease; Lupus Nephritis
Details
Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine)Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of MedicineLupus Erythematosus, Systemic; Nephrosis
Details
REVO-UWD-00BREVO-UWD-00B; UWD-00BPhase 1 ClinicalWondercel Therapeutics Co LtdMultiple Myeloma
Details
ESO-T01ESO-T01Phase 1 ClinicalEsoBiotec SAMultiple Myeloma
Details
UF-KURE-BCMA CAR-T Cells therapy(University Hospitals Cleveland Medical Center)Phase 1 ClinicalUniversity Hospitals Cleveland Medical CenterMultiple Myeloma
Details
68Ga-BC168Ga-BC1Phase 1 ClinicalThe First Affiliated Hospital Of Beijing UniversityMultiple Myeloma; Neoplasms, Plasma Cell
Details
CT-0596CT-0596; CT0596Phase 1 ClinicalCarsgen Biomedicine (Shanghai) Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
RD06-05RD06-05Phase 1 ClinicalNanjing Bioheng Biotech Co LtdAnemia, Hemolytic, Autoimmune; Anti-Glomerular Basement Membrane Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Encephalitis; Evans syndrome; Glomerulonephritis; Graves Disease; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Multiple Sclerosis; Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic; Scleroderma, Systemic
Details
Anti-CD19/BCMA CAR NK cells therapy(The Children's Hospital of Zhejiang University School of Medicine)KN5601; KN-5601Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of MedicineArthritis; Autoimmune Diseases; Glomerulonephritis, IGA; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Mucocutaneous Lymph Node Syndrome; Nephrosis; Rheumatic Diseases
Details
CAR19BCMA-T cells therapy(The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital))Phase 1 ClinicalThe Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital)Neoplasms, Plasma Cell
Details
RN-1101 (Rui Therapeutics)RN-1101Phase 1 ClinicalShenzhen Rui Therapeutics Co LtdLymphoma, B-Cell; Multiple Myeloma
Details
SL-0439SL0439; SL-0439Phase 1 ClinicalHebei Senlang Biological Technology Co LtdMultiple Myeloma
Details
Meta10-BCMAMeta10-BCMAPhase 1 ClinicalAnhui Provincial HospitalImmunoglobulin Light-chain Amyloidosis; Leukemia, Plasma Cell; Multiple Myeloma
Details
OriV-508OriV508; OriV-508Phase 1 ClinicalWuhan Medical Care Center For Women And ChildrenLymphoma, Non-Hodgkin; Multiple Myeloma
Details
RN-1201RN-1201; RN1201Phase 1 ClinicalThe First Affiliated Hospital Of Soochow UniversityThrombocytopenia
Details
QM-103QM-103; QM103Phase 1 ClinicalBeijing Qimai Yonghua Biotechnology Co LtdMultiple Myeloma
Details
Allogeneic, Umbilical Cord Blood-derived, Dual-targeting BCMA/CD19 CAR-T Therapy (Ucello)Phase 1 ClinicalUcello Therapeutics Co LtdLupus Erythematosus, Systemic; Multiple Myeloma
Details
Fully Human BCMA-Targeted Chimeric Antigen Receptor Autologous T-Cell therapy (Institute of Hematology & Blood Diseases Hospital)CT103dPhase 1 ClinicalInstitute Of Hematology & Blood Diseases HospitalLeukemia, Plasma Cell; Multiple Myeloma
Details
KT-501KT501; KT-501Phase 1 ClinicalKali Therapeutics IncArthritis, Rheumatoid
Details
Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells therapy (Rui Therapeutics)KN-3601; KN3601Phase 1 ClinicalShenzhen Rui Therapeutics Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic; Nephrosis; Scleroderma, Systemic; Sjogren's Syndrome
Details
TPST-2003TPST-2003Phase 1 ClinicalFactor Bioscience IncMultiple Myeloma
Details
CAR19-BCMA dual-target CAR-T cell therapy (Tahoe Chunyu Biotechnology)Phase 1 ClinicalHebei Tahoe Chunyu Biotechnology Co LtdMultiple Myeloma
Details
NPB5005-V283NPB5005-V283Phase 1 ClinicalNeomics Pharmaceuticals LLCMultiple Myeloma
Details
Fully-Human Anti-BCMA CAR therapy (NIH)Phase 1 ClinicalNational Cancer InstituteMultiple Myeloma
Details
UCAR T-cell therapy (The Children'S Hospital, Zhejiang University School Of Medicine)Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of MedicineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoimmune Diseases; Glomerulonephritis, IGA; Lupus Erythematosus, Systemic; Nephrosis; Scleroderma, Systemic
Details
IASO-206IASO206; IASO-206Phase 1 ClinicalInstitute Of Hematology & Blood Diseases HospitalMultiple Myeloma
Details
Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy (Beijing Gao Boren Hospital)Phase 1 ClinicalBeijing Gao Boren Hospital Co LtdAnemia, Hemolytic, Autoimmune; Lupus Erythematosus, Systemic; Multiple Sclerosis; Scleroderma, Systemic; Sjogren's Syndrome
Details
O&D-001O&D-001Phase 1 ClinicalO&D BioTech Group Co LtdMultiple Myeloma
Details
CD19/BCMA in vivo CAR-T cell therapy (West China Hospital Of Sichuan University)Phase 1 ClinicalWest China Hospital Of Sichuan UniversityAutoimmune Diseases
Details
CAR BCMA-CD70-T cells therapy (The Fifth Medical Center Of Pla General Hospital)Phase 1 ClinicalThe Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital)Neoplasms, Plasma Cell
Details
BCMA-Targeted CAR T-Cell therapy (Chulalongkorn University)Phase 1 ClinicalChulalongkorn UniversityMultiple Myeloma
Details
Allogeneic CD19/BCMA-targeted CAR-γδT cell therapy (Institute Of Hematology & Blood Diseases Hospital)Phase 1 ClinicalInstitute Of Hematology & Blood Diseases HospitalAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lupus Erythematosus, Systemic; Myositis; Scleroderma, Systemic; Thrombocytopenia
Details
P-BCMA-ALLO1P-BCMA-ALLO1; RG-6538Phase 1 ClinicalJanssen Biotech Inc, Transposagen Biopharmaceuticals IncMultiple Myeloma
Details
FT-576FT-576Phase 1 ClinicalFate Therapeutics Inc, University Of MinnesotaBone Marrow Neoplasms; Multiple Myeloma
Details
CB-011CB-011Phase 1 ClinicalCaribou Biosciences IncMultiple Myeloma
Details
ACLX-001ACLX-001Phase 1 ClinicalArcellx IncMultiple Myeloma
Details
DXC-009DXC-009Phase 1 ClinicalHangzhou Dac Biotech Company LtdMultiple Myeloma
Details
SA102-CAR-TSA-102; SA102Phase 1 ClinicalWuhan Sian Biotechnology Co LtdMultiple Myeloma
Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology)Phase 1 ClinicalShengyan Pharmaceutical TechnologyMultiple Myeloma
Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics)Phase 1 ClinicalIcell Gene Therapeutics (Int'L) LtdLupus Erythematosus, Systemic; Multiple Myeloma; Pancytopenia; Waldenstrom Macroglobulinemia
Details
CART-BCMAMTV-273; CART-BCMAPhase 1 ClinicalUniversity Of PennsylvaniaKidney Failure, Chronic; Multiple Myeloma; Rejection of renal transplantation; Renal Insufficiency
Details
PavurutamabAMG-701Phase 1 ClinicalAmgen IncMultiple Myeloma
Details
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)Phase 1 ClinicalThe First Affiliated Hospital Of Nanchang UniversityMultiple Myeloma
Details
AlnuctamabEM-901; BMS-986349; CC-93269Phase 1 ClinicalEngmab AgLupus Erythematosus, Systemic; Multiple Myeloma
Details
Nendocabtagene onogedleucelALLO-715Phase 1 ClinicalCellectis SaMultiple Myeloma
Details
AMG-224AMG-224Phase 1 ClinicalAmgen IncMultiple Myeloma
Details
bb-21217bb-21217Phase 1 ClinicalBristol-Myers Squibb Company, Genetix Biotherapeutics IncMultiple Myeloma
Details
ACTR 087/SEA BCMA combination therapyPhase 1 ClinicalUnum Therapeutics IncMultiple Myeloma
Details
PodentamigHPN-217; BCMA TriTACPhase 1 ClinicalAbbvie Inc, Harpoon TherapeuticsMultiple Myeloma
Details
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma; Neoplasms
Details
Revlucabtagene AutoleucelHBI-0101; NXC-201Phase 2 ClinicalHadassah Medical Organization, Immix Biopharma IncArthritis, Rheumatoid; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Multiple Myeloma; Myositis; Scleroderma, Systemic
Details
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical)Phase 2 ClinicalShandong New Time Pharmaceutical Co LtdLupus Erythematosus, Systemic; Multiple Myeloma
Details
F-182112F182112; F-182112Phase 2 ClinicalShandong New Time Pharmaceutical Co LtdLupus Erythematosus, Systemic; Multiple Myeloma
Details
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital)Phase 2 ClinicalShenzhen University General HospitalMultiple Myeloma
Details
Descartes-11Descartes-11; Descartes-011Phase 2 ClinicalCartesian Therapeutics IncMultiple Myeloma
Details
ARI-0002hARI-0002hPhase 2 ClinicalInstituto De Salud Carlos IiiMultiple Myeloma
Details
CAR-BCMA(Sheba Medical Center)Phase 2 ClinicalSheba Medical Center, IsraelMultiple Myeloma
Details
TQB-2934TQB2934; TQB-2934Phase 2 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupAmyloidosis; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Neoplasms, Plasma Cell
Details
Anti-BCMA/GPRC5D Bispecific CAR T cell therapy (Shanghai YaKe Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma
Details
SNC-102 (Shanghai Simnova Biotechnology)SNC102; CART-BCMAPhase 2 ClinicalShanghai Simnova Biotechnology Co LtdMultiple Myeloma
Details
BelantamabGSK2857914; GSK-2857914Phase 2 ClinicalGlaxosmithkline PlcAutoimmune Diseases; Multiple Myeloma
Details
MBS-314MBS-314Phase 2 ClinicalBeijing Mabworks Biotech Co LtdMultiple Myeloma
Details
CART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital)Phase 2 ClinicalInstitute Of Hematology & Blood Diseases HospitalMultiple Myeloma
Details
BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene)Phase 2 ClinicalGuangzhou Bio-Gene Technology Co LtdMultiple Myeloma
Details
IBI-3003IBI3003; IBI-3003Phase 2 ClinicalMultiple Myeloma
Details
C-CAR168C-CAR168Phase 2 ClinicalCellular Biomedicine (Shanghai) Co LtdAutoimmune Diseases; Encephalitis; Lupus Erythematosus, Systemic; Lupus Nephritis; Multiple Sclerosis; Muscular Diseases; Myasthenia Gravis; Neuromyelitis Optica; Scleroderma, Systemic; Stiff-Person Syndrome
Details
Anti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences)Phase 2 ClinicalShahid Beheshti University Of Medical SciencesMultiple Myeloma
Details
Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech)Phase 2 ClinicalEssen BiotechAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoimmune Diseases; Granulomatosis with Polyangiitis; Lupus Erythematosus, Systemic; Lupus Nephritis; Microscopic Polyangiitis; Myositis; Scleroderma, Systemic; Sjogren's Syndrome
Details
CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute)Phase 2 ClinicalShenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of HealthMultiple Myeloma; Plasmacytoma
Details
Nanobody-based biepitope BCMA-targeting CAR-T cells therapy(Tahoe Chunyu Biotechnology)Phase 2 ClinicalHebei Tahoe Chunyu Biotechnology Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
SENL-103SENL-103; S-103Phase 2 ClinicalHebei Senlang Biological Technology Co LtdAmyloidosis; Multiple Myeloma; Multiple Sclerosis; Myasthenia Gravis
Details
BCD-248BCD-248Phase 2 ClinicalBIOCAD JSCMultiple Myeloma
Details
Chimeric Antigen Receptor Modified T Cells Targeting BCMA(The First Affiliated Hospital of Xiamen University)Phase 2 ClinicalThe First Affiliated Hospital Of Xiamen UniversityMultiple Myeloma
Details
BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital)Phase 2 ClinicalShenzhen University General HospitalMultiple Myeloma
Details
ICG-318ICG-318; ICG318Phase 2 ClinicalSonghe Immunobiological Medical (Shenzhen) Co LtdLupus Erythematosus, Systemic; Lupus Nephritis
Details
anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)Multiple Myeloma
Details
QT-019BQT-019BPhase 2 ClinicalHangzhou Qihan Biotechnology Co LtdAnemia, Hemolytic, Autoimmune; Autoimmune Diseases; Lupus Erythematosus, Systemic; Myasthenia Gravis
Details
VonsetamigREGN-5459Phase 2 ClinicalRegeneron Pharmaceuticals IncLupus Nephritis; Multiple Myeloma; Renal Insufficiency, Chronic
Details
SL-1703SL1703; SL-1703Phase 2 ClinicalHebei Senlang Biological Technology Co LtdLupus Nephritis; Multiple Myeloma; Scleroderma, Systemic
Details
BCMA/GPRC5D targeting chimeric antigen receptor T cell therapy (Essen Biotech)Phase 2 ClinicalEssen BiotechMultiple Myeloma
Details
BCMA CAR-T Cell Therapy (Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)Multiple Myeloma
Details
Anti-BCMA-CD19 CAR-T cells therapy (Pla General Hospital)Phase 2 ClinicalPla General HospitalAutoimmune Diseases; Immunoglobulin G4-Related Disease
Details
Anti BCMA CAR-T cells therapy (Minsk Scientific-Practical Center For Surgery, Transplantation And Hematology)Phase 2 ClinicalMinsk Scientific-Practical Center For Surgery, Transplantation And HematologyMultiple Myeloma
Details
Pamlectabart tismanitinHDP101-ATAC; HDM2027; HDP-101Phase 2 ClinicalHeidelberg Pharma AGHematologic Diseases; Multiple Myeloma; Paraproteinemias
Details
KQ-2003KQ-2003; KQ2003Phase 2 ClinicalShanghai Keqi Pharmaceutical Technology Co LtdMultiple Myeloma; POEMS Syndrome; Solid tumours
Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army)Phase 2 ClinicalPeople'S Liberation Army General Hospital Military ServiceMultiple Myeloma
Details
Orvacabtagene autoleucelET140-CAR; MCARH-171; JCARH-125; FCARH-143; ET-140Phase 2 ClinicalFred Hutchinson Cancer Research CenterMultiple Myeloma
Details
C-CAR088C-CAR088Phase 2 ClinicalCellular Biomedicine (Shanghai) Co LtdMultiple Myeloma
Details
Anti-BCMA chimeric antigen receptor T cell therapy (Shanghai Unicar-Therapy Bio-medicine Technology)Phase 2 ClinicalShanghai Unicar-Therapy Bio-Medicine Technology Co LtdLeukemia; Multiple Myeloma
Details
BCMA CAR-T cell therapy (Chongqing Precision Biotech)Phase 2 ClinicalChongqing Precision Biotechnology Co LtdMultiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma
Details
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech)Phase 2 ClinicalChongqing Precision Biotechnology Co LtdLymphoma, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma
Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology)BCMA-CART; HR003Phase 2 ClinicalHrain Biotechnology Co LtdMultiple Myeloma
Details
BCMA CAR-T Cells (Pregene)PRG-1801; GLPG-5301; DRL-1801Phase 2 ClinicalShenzhen Pregene Biopharma Co LtdImmunoglobulin G4-Related Disease; Lupus Nephritis; Multiple Myeloma; Purpura, Thrombocytopenic, Idiopathic
Details
GamgertamigCM-336; OM336Phase 3 ClinicalKeymed Biosciences Co LtdAmyloidosis; Anemia, Hemolytic, Autoimmune; Cytopenia; Evans syndrome; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome; Skin Diseases, Vesiculobullous
Details
VelinotamigGR-1803Phase 3 ClinicalChongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co LtdAutoimmune Diseases; Lupus Erythematosus, Systemic; Multiple Myeloma
Details
RamantamigJNJ-79635322; JNJ-5322Phase 3 ClinicalJanssen Research & Development LlcMultiple Myeloma
Details
BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital)Phase 3 ClinicalPeking University People'S HospitalAcquired thrombotic thrombocytopenic purpura; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Behcet Syndrome; Carcinoma, Transitional Cell; Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic; Myositis; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome
Details
GC-012FAZD0120; GC-012F; GC012F; AZD-0120Phase 3 ClinicalGracell Biotechnologies (Shanghai) Co LtdAmyloidosis; Arthritis, Rheumatoid; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Multiple Sclerosis; Myasthenia Gravis; Myositis; Scleroderma, Systemic
Details
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian)Descartes-08Phase 3 ClinicalCartesian Therapeutics IncAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Anti-synthetase Syndrome; Dermatomyositis; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis
Details
EtentamigTNB-383B; ABBV-383Phase 3 ClinicalTeneoOne IncImmunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Waldenstrom Macroglobulinemia
Details
Anitocabtagene autoleucelKite-772; CART-ddBCMAPhase 3 ClinicalArcellx IncAutoimmune Diseases; Autoimmune Diseases of the Nervous System; Multiple Myeloma; Muscle Weakness; Muscular Diseases; Myasthenia Gravis; Neuromuscular Manifestations
Details
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University)Phase 3 ClinicalThe First Affiliated Hospital Of Soochow UniversityLeukemia; Multiple Myeloma
Details
GenSci-136GenSci136Phase 1 ClinicalChangchun GeneScience Pharmaceuticals Co LtdAutoimmune Diseases; Glomerulonephritis, IGA; Lupus Erythematosus, Systemic; Myasthenia Gravis; Sjogren's Syndrome
Details
Autologous CAR-T cell therapy expressing the BAFF-ligandLMY-920; LUMT1A22Phase 1 ClinicalLuminary Therapeutics IncLupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Multiple Myeloma; Scleroderma, Systemic; Sjogren's Syndrome
Details
dual anti-CD19/anti-BAFF CAR T-cell therapy (Shanghai YaKe Biotechnology/Zhejiang University)Phase 1 ClinicalShanghai Yake Biotechnology Co LtdAutoimmune Diseases; Dermatomyositis; Lupus Erythematosus, Systemic; Nephritis; Neuromyelitis Optica; Scleroderma, Systemic
Details
UBP-1213UBP-1213; UBP 1213scPhase 1 ClinicalWuhan Huaxin Kangyuan Biomedicine Co LtdLupus Erythematosus, Systemic
Details
Rozibafusp alfaMEDI-0700; AMG-570Phase 2 ClinicalAmgen IncArthritis, Rheumatoid; Lupus Erythematosus, Systemic
Details
TibulizumabLY-3090106; LY3090106; ZB-106Phase 2 ClinicalEli Lilly And CompanyArthritis, Rheumatoid; Hidradenitis Suppurativa; Scleroderma, Systemic; Sjogren's Syndrome; Sjogren-Larsson Syndrome
Details
PovetaciceptALPN-303; ALPN 30xPhase 3 ClinicalAlpine Immune Sciences IncAnemia, Hemolytic, Autoimmune; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cytopenia; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Inflammation; Lupus Erythematosus, Systemic; Lupus Nephritis; Myasthenia Gravis; Nephrosis; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome
Details

Resources

  • Background
  • Product Features
  • Product List
  • Validated Data
  • Clinical Drug Information Table of BAFF-APRIL Pathway
  • Resources